Monograph

S01LA05 - Aflibercept

Not porphyrinogenic

Rationale

Aflibercept is a fusion protein and is not metabolized by CYP enzymes. No potential porphyrinogenic effects are expected.

Chemical description

Aflibercept is a recombinant fusion protein.

Therapeutic characteristics

Aflibercept is indicated for the treatment of neovascular (wet) age-related macular degeneration. Visual impairment due to macular degeneration secondary to retinal vein occlusion, diabetic macular oedema or due to myopic choroidal neovascularization. Aflibercept is administered by intravitreal injections.

Hepatic exposure

A small amount of the drug enters the systemic circulation (Avary 2014).

Metabolism and pharmacokinetics

Free aflibercept binds to vascular endothelial growth factor to form a stable, inert complex. As with other large proteins, both free and bound aflibercept are expected to be cleared by proteolytic catabolism (SPC). The cytochrome P450 enzyme system is not involved in the metabolism of aflibercept (drugbank).

Similar drugs

Explore alternative drugs in similar therapeutic classes S01L / S01LA or go back.

References

#	Citation details	PMID
*	Scientific articles
1.	systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Avary RL et al. Br J Ophthalmology. 2014; 98 (12): 1636-1641.	24795335
*	Drug reference publications
2.	DrugBank. Aflibercept.
*	Summary of Product Characteristics
3.	The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Eylea.

Citation details

PMID

Scientific articles

systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD.

Avary RL et al. Br J Ophthalmology. 2014; 98 (12): 1636-1641.

24795335

Drug reference publications

DrugBank. Aflibercept.

Summary of Product Characteristics

The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Eylea.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames

Afqlir 40 mg/ml oplossing voor injectie in een injectieflacon · Afqlir 40 mg/ml oplossing voor injectie in een voorgevulde spuit · Ahzantive 40 mg/ml oplossing voor injectie in een injectieflacon · Baiama 40 mg/ml oplossing voor injectie in een injectieflacon · Eydenzelt 40 mg/ml oplossing voor injectie in een injectieflacon · Eydenzelt 40 mg/ml oplossing voor injectie in een voorgevulde spuit · Eylea 114,3 mg/ml oplossing voor injectie · Eylea 40 mg/ml oplossing voor injectie (in voorgevulde spuit of injectieflacon) · Opuviz 40 mg/ml oplossing voor injectie in een injectieflacon · Yesafili 40 mg/ml oplossing voor injectie in een injectieflacon

Afqlir · Afqlir 40 mg/ml sol. inj. i.vitr. flac. · Afqlir 40 mg/ml sol. inj. i.vitr. ser. pr?remplie · Ahzantive 40 mg/ml sol. inj. i.vitr. flac. · Baiama · Baiama 40 mg/ml sol. inj. i.vitr. ser. pr?remplie · Eylea · Eylea 114.3 mg/ml sol. inj. i.vitr. flac. · Eylea 114.3 mg/ml sol. inj. i.vitr. ser. pr?remplie · Eylea 40 mg/ml sol. inj. i.vitr. flac. · Eylea 40 mg/ml sol. inj. i.vitr. ser. pr?remplie · Opuviz 40 mg/ml sol. inj. i.vitr. flac. · Yesafili 40 mg/ml sol. inj. i.vitr. flac.

Afqlir 40 mg/ml Solucion Inyectable en Jeringa Precargada · Afqlir 40 mg/ml Solucion Inyectable en Vial · Eylea · Eylea 40 mg/ml Solucion Inyectable en Jeringa Precargada · Eylea 40 mg/ml Solucion Inyectable en Vial